AACR 2023 Conference Coverage

 

AACR 2023 Conference Coverage
A

Safety & Efficacy From the Phase 1/2 First-in-Human Study of REGN5459, a BCMA×CD3 Bispecific Antibody With Low CD3 Affinity, in Patients With R/R MM

By AACR 2023 Conference Coverage FEATURING Attaya Suvannasankha
By AACR 2023 Conference Coverage FEATURING Attaya Suvannasankha
180 views
May 12, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Videos
11:12

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clin…

AACR 2023 Conference Coverage

M. Gouda

126 views
12:13

Clinical Activity of MCLA-158 (Petosemtamab), an IgG1 Bispecific Ant…

AACR 2023 Conference Coverage

E. Cohen

206 views
10:22

Understanding the Disease Biology of B-ALL: Insights From Genomic an…

AACR 2023 Conference Coverage

I. Iacobucci

60 views
09:13

Safety & Efficacy From the Phase 1/2 First-in-Human Study of REGN545…

AACR 2023 Conference Coverage

A. Suvannasankha

180 views
09:05

AACR 2023 on KEYNOTE-966 Phase 3 Study: Pembro in Combination With G…

AACR 2023 Conference Coverage

K. Kelley

352 views
16:00

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resec…

AACR 2023 Conference Coverage

J. Weber

341 views
13:53

First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor…

AACR 2023 Conference Coverage

T. Yap

61 views